Resmed Inc

Análisis de la acción Resmed Inc (RMD)

$238.970

-3.226 (-1.35%)Al cierre

Loading chart…
Máximo
242.575
Apertura
241.540
Precio medio ponderado por volumen
239.80
Volumen
2.55M
Capitalización
28.14B
Mínimo
237.870
Importe
610.71M
EV/EBITDA, TTM
15.49

ResMed Inc. is a holding company. The Company, through its subsidiaries, in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease, neuromuscular disease and other chronic diseases. Its segments include Sleep and Breathing Health segment and the Residential Care Software segment. It also operates a Software as a Service (SaaS) business in the United States and Germany that includes out-of-hospital software platforms designed to support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. Its products and solutions are designed to improve patients' quality of life and reduce the impact of chronic disease. Its cloud-based digital health software applications, along with its devices, are designed to provide connected care.

www.resmed.com

Análisis de IA of Resmed Inc (RMD)

Comprar

ResMed Inc. is a good buy right now due to its current price of $238.97 being below the analyst price targets of $262 and $267, indicating significant upside potential. The stock has shown a strong RSI of 72.818, suggesting bullish momentum, and a solid gross margin of 58.12%, indicating good profitability. However, the recent insider selling by the CEO, who sold nearly 5,000 shares, may raise concerns about future performance, which is a risk to consider.

Recomendaciones de analistas (10)

+23.03% de potencial alcista
Comprar
4 Comprar
2 Mantener
4 Vender
Actual: 238.97
Mínimo
260.00
Promedio
294.00
Máximo
345.00

RBC Capital

2026-09-15

Precio objetivo

$262

Superar al mercado

Citi

2026-09-10

Precio objetivo

$240

Neutral

KeyBanc

2026-08-31

Precio objetivo

$267

Sobreponderar

Rothschild & Co Redburn

2026-08-19

Precio objetivo

$230

Neutral

RBC Capital

2026-08-07

Precio objetivo

$244

Sector Perform

Métricas de valoración

El PER previsto actual de Resmed Inc (RMD) es 18.52, frente a su media de 5 años de 25.85.

PER previsto

Valor razonable
Media 5A P/E
25.85
P/E actual
18.52
Sobrevalorada
34.14
Infravalorada
17.55

EV/EBITDA previsto

Valor razonable
Media 5A EV/EBITDA
19.60
EV/EBITDA actual
15.49
Sobrevalorada
24.23
Infravalorada
14.97

Precio/ventas previsto

Valor razonable
Media 5A P/S
6.73
P/S actual
5.49
Sobrevalorada
8.04
Infravalorada
5.42

Escenarios de precio de Alphio AI para RMD

Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.

A

Alcista

Alcista · 25%RMD

$284.42

Precio del escenario

B

Base

Base · 50%RMD

$251.26

Precio del escenario

B

Bajista

Bajista · 25%RMD

$215.34

Precio del escenario

Ballenas con RMD en cartera

W

Walter Scott & Partners Limited

+ Con en carteraRMD

+6.20%

Rentabilidad a 3 meses

W

Welch & Forbes LLC

+ Con en carteraRMD

+4.44%

Rentabilidad a 3 meses

A

American Capital Management, Inc.

+ Con en carteraRMD

+1.32%

Rentabilidad a 3 meses

G

Giverny Capital Inc.

+ Con en carteraRMD

+1.23%

Rentabilidad a 3 meses

T

The MassMutual Trust Company, F.S.B., Trust Investments

+ Con en carteraRMD

+0.04%

Rentabilidad a 3 meses

I

Ilex Capital Partners (Uk) LLP

+ Con en carteraRMD

-0.03%

Rentabilidad a 3 meses

Cronología de eventos

2026-09-01 (ET)

09:00:00

Resmed Completes Sale of MatrixCare to Frazier Healthcare

2026-08-06 (ET)

19:00:00

Stock Futures Mixed as Doximity Soars 83.93%

16:30:00

ResMed Increases Quarterly Dividend by 10% to 66 Cents

16:30:00

Resmed Reports Q4 Revenue of $1.46B

Noticias

Preguntas frecuentes sobre RMD, respondidas por Alphio AI

ResMed Inc. is a holding company. The Company, through its subsidiaries, in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease, neuromuscular disease and other chronic diseases. Its segments include Sleep and Breathing Health segment and the Residential Care Software segment. It also operates a Software as a Service (SaaS) business in the United States and Germany that includes out-of-hospital software platforms designed to support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. Its products and solutions are designed to improve patients' quality of life and reduce the impact of chronic disease. Its cloud-based digital health software applications, along with its devices, are designed to provide connected care. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

ResMed Inc. is a good buy right now due to its current price of $238.97 being below the analyst price targets of $262 and $267, indicating significant upside potential. The stock has shown a strong RSI of 72.818, suggesting bullish momentum, and a solid gross margin of 58.12%, indicating good profitability. However, the recent insider selling by the CEO, who sold nearly 5,000 shares, may raise concerns about future performance, which is a risk to consider.

10 analysts cover RMD: 4 rate it Buy, 2 Hold and 4 Sell. The average price target is 294.00.

Comunidad

Más ↗

Aún no hay publicaciones

Regístrate o inicia sesión para participar

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empezar a operar